Efficacy of pemetrexed or docetaxel plus cisplatin in treatment of patients with non-small cell lung cancer
PEI Bao-xiang
SHAN Wen-zhi
WANG wei
Abstract：Objective To compare the efficacy and toxicity of pemetrexed ordocetaxel plus cisplatin in treatment of patients with non-small cell lung cancer (NSCLC).Methods All 54 patients with NSCLC were enrolled in the study.The pemetrexed group (n =28) were treated with pemetrexed (500-600 mg/m2) combined cisplatin (75 mg/m2d1).The docetaxel group (n =26) were treated with docetaxel (70-80 mg/m2) combined with cisplatin (75 mg/m2d1).Both groups were given dexamethasone to prevent allergy.Twenty-one days were acted as one course,and the effect was evaluated after at least two courses.Results The remission rate and disease control rate in pemetrexed group and docetaxel group were 35.7％ (10/28),85.7％ (24/28) and 34.6％ (9/26),84.6％(22/26) respectively (P ＞ 0.05).The side effect (hematologic toxicity and alopecia) incidence rate in the pemetrexed group was significantly lower than that in the docetaxel group [50.0％ (14/28) vs 65.4％ (17/26),0 vs 23.1％ (6/26),all P ＜ 0.05].Conclusion The efficacy of pemetrexed combined cisplatin and cocetaxel combined csplatin for the treatment of NSCLC patients have no significant difference,while the side effect incidence rate shows significant difference.
Keywords：Carcinomanon-small cell lungPemetrexedDocetaxelCurative effectAdverse reaction
Publication Date：2013-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：2( 1566-1567 )